公司资料
Cardiff Oncology 股价、新闻与催化剂
- 股票代码:
- CRDF
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.18 USD (-2.48%)
收盘价
最后更新: 2026年10月1日
103M USD
市值
股价为何变动
截至 2026年10月1日，CRDF 下跌 2.48%，收于 $1.18。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Cardiff Oncology is an oncology company focused on precision cancer therapy and cell-cycle biology. Its development strategy is centered on targeted treatment combinations for solid tumors.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Cardiff sits in specialty oncology biotechnology.
商业模式特征
The business depends on clinical data, pathway validation, and the ability to create a differentiated oncology franchise.
生物医药行业定位
Cardiff is a small-cap oncology catalyst name whose stock moves on early clinical readouts.
未来催化剂
- Cardiff Oncology’s catalysts are onvansertib and the KRAS-driven oncology program, especially any new combination or clinical data that keep the story alive. The company remains highly dependent on proof of differentiation.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。